Amarantus BioSciences
Sunnyvale
About Amarantus BioSciences
Amarantus BioSciences is a development-stage, publicly-traded biotechnology company discovering and developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis. The company focuses on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine, and diagnostics in neurology. its prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.3M
- Last round: Series Unknown (Nov 2014)
- Website: amarantus.com
- Phone: (415) 688-4484
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/amarantus-biosciences-2751193 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.